By Dr Tamara Yael Milder

Journal articles

Kam PCA; Milder TY; Milder DA, 2024, 'Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists: a reply', Anaesthesia, 79, pp. 1133, http://dx.doi.org/10.1111/anae.16369

de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO, 2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes, Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597

Milder DA; Milder TY; Liang SS; Kam PCA, 2024, 'Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice', Anaesthesia, 79, pp. 735 - 747, http://dx.doi.org/10.1111/anae.16306

Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2024, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, 54, pp. 559 - 567, http://dx.doi.org/10.1111/imj.16203

Milder TY; Lin J; Pearson SA; de Oliveira Costa J; Neuen BL; Pollock C; Jun M; Greenfield JR; Day RO; Stocker SL; Brieger D; Falster MO, 2024, 'Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?', Diabetes, Obesity and Metabolism, http://dx.doi.org/10.1111/dom.16061

Milder DA; Milder TY; Kam P, 2024, 'Preoperative GLP-1 Receptor Agonists and Risk of Postoperative Respiratory Complications', JAMA, http://dx.doi.org/10.1001/jama.2024.10029

Milder TY; Lin J; Pearson SA; Greenfield JR; Day RO; Stocker SL; Neuen BL; Falster MO; de Oliveira Costa J, 2024, 'Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/bcp.16231

Milder TY; Milder DA; Greenfield JR; Day RO, 2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305, http://dx.doi.org/10.1007/s40264-023-01358-5

Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419, http://dx.doi.org/10.1111/anae.16068

Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676, http://dx.doi.org/10.1111/imj.15727

Milder T; Stocker S; Baysari M; Day R; Greenfield J, 2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, 31, pp. S96 - S97, http://dx.doi.org/10.1016/j.hlc.2022.06.117

Milder TY; Stocker SL; Baysari M; Day RO; Greenfield JR, 2021, 'Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists', Diabetes Research and Clinical Practice, 180, http://dx.doi.org/10.1016/j.diabres.2021.109036

Milder T; Stocker S; Baysari M; Day RO; Greenfield J, 2021, 'Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists', DIABETES, 70, http://dx.doi.org/10.2337/db21-779-P

Milder TY; Stocker SL; Day RO; Greenfield JR, 2020, 'Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease', Drug Safety, 43, pp. 1211 - 1221, http://dx.doi.org/10.1007/s40264-020-01010-6

Milder TY; Day RO; Stocker SL; Greenfield JR, 2020, 'Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes', Internal Medicine Journal, 50, pp. 645 - 646, http://dx.doi.org/10.1111/imj.14819

, 2019, 'Book review: Therapeutic Guidelines: Diabetes. Version 1', Australian Prescriber, 42, pp. 205 - 205, http://dx.doi.org/10.18773/austprescr.2019.063

Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR, 2019, 'Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease', European Journal of Clinical Pharmacology, 75, pp. 1481 - 1490, http://dx.doi.org/10.1007/s00228-019-02732-y

Milder TY; Stocker SL; Shaheed CA; McGrath-Cadell L; Samocha-Bonet D; Greenfield JR; Day RO, 2019, 'Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis', JOURNAL OF CLINICAL MEDICINE, 8, http://dx.doi.org/10.3390/jcm8010045

Milder DA; Milder TY; Kam PCA, 2018, 'Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations', Anaesthesia, 73, pp. 1008 - 1018, http://dx.doi.org/10.1111/anae.14251

Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514

Back to profile page